longbridge

JD HEALTH

06618
----

  • Weekly Recap | JD HEALTH -2.49%, consensus target above spot

    Weekly Review·
    - JD Health closed the week at 37.6 HKD, marking a cumulative decline of 2.49% while outperforming the Hang Seng Index by approximately 2.03 percentage points. - Seventeen institutions have given the company a consensus rating of strong buy, with a consensus target price of 68.72 HKD, which is about 82.77% higher than its current price. - The company is scheduled to release its financial results for the third quarter of fiscal year 2026 after the market closes on November 13.
    06618+0.16%

  • Weekly Recap | JD HEALTH +6.93%, most brokers rate it buy

    Weekly Review·
    - JD Health accumulated a 6.93 % increase this week, closing at 38.56 HKD and outperforming the Hang Seng Index by 7.28 percentage points. - The company advanced offline medical services, initiated the 11.11 grand promotion, and participated in the Senior Care Exhibition. - Seventeen coverage institutions gave ratings with 13 buys, 3 overweight, and 1 neutral, leading to an average target price of 68.58 HKD.
    06618+0.16%
© 2026 Longbridge｜Terms of ServicePrivacy Policy